Lee, Danner & Bass’s Biogen BIIB Stock Holding History

Lee, Danner & Bass’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-161	Closed	-$24.6K	–	271
2024 Q4	$24.6K	Buy	+161	New	+$27.2K	﹤0.01%	435

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Lee, Danner & Bass's BIIB Position: Q1 2025 in Review

Lee, Danner & Bass sold out of Biogen (BIIB) in Q1 2025, closing a stake of 161 shares — an estimated $24.6K sold.

Lee, Danner & Bass first reported a position in BIIB in Q4 2024 and held it in 1 quarter. The position peaked at $24.6K in Q4 2024. 883 funds tracked by Wall St. Rank hold BIIB as of Q1 2025.

Lee, Danner & Bass reported no remaining Biogen position as of Q1 2025 after selling out during the quarter.
Lee, Danner & Bass sold 161 Biogen shares in Q1 2025, an estimated $24.6K.
Lee, Danner & Bass first reported a position in Biogen in Q4 2024 and held it in 1 quarter.
Lee, Danner & Bass's Biogen position peaked at $24.6K in Q4 2024.
883 funds tracked by Wall St. Rank held Biogen as of Q1 2025.

Based on Lee, Danner & Bass's 13F filing for Q1 2025, filed 29 Apr 2025.